AI English summary of an SEC filing — figures as filed
CRH CRHCRH said Adjusted EBITDA rose 15% to $6.2 billion in 2023 (2022: $5.4 billion), and earnings per share rose 22% to $4.36 (2022: $3.58). Net income for the same period was $3.1 billion (2022: $3.9 billion), and EPS excluding the non-cash impairment charge was $4.65.
Key points
AI summaryCRH said Adjusted EBITDA rose 15% to $6.2 billion in 2023 (2022: $5.4 billion), and earnings per share rose 22% to $4.36 (2022: $3.58). Net income for the same period was $3.1 billion (2022: $3.9 billion), and EPS excluding the non-cash impairment charge was $4.65.
The company said it repurchased 54.9 million ordinary shares for a total of $3.0 billion in 2023 (2022: 29.8 million shares, $1.2 billion), and increased total dividend per share for 2023 by 5%. It said the board extended the program to complete an additional tranche of $0.3 billion by May 9, 2024.
CRH said shareholders approved the company's transition to a primary listing on the NYSE at an extraordinary general meeting on June 8, 2023, which is the 1st listing change, and that the listing changes took effect on September 25, 2023. The company said North America accounts for about 75% of Adjusted EBITDA.
The company said it will hold its April 25, 2024 annual general meeting to vote on 7 items, including the re-election of 13 directors and an advisory vote on executive compensation. The record date for voting rights is March 14, 2024, and the Board recommends voting in favor of all items.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
2023 Adjusted EBITDA, EPS and Net Income
CRH said Adjusted EBITDA rose 15% to $6.2 billion in 2023 (2022: $5.4 billion), and earnings per share rose 22% to $4.36 (2022: $3.58). Net income for the same period was $3.1 billion (2022: $3.9 billion), and EPS excluding the non-cash impairment charge was $4.65.
Source · Based on the filing body and exhibits
2023 Share Buybacks and Dividends
The company said it repurchased 54.9 million ordinary shares for a total of $3.0 billion in 2023 (2022: 29.8 million shares, $1.2 billion), and increased total dividend per share for 2023 by 5%. It said the board extended the program to complete an additional tranche of $0.3 billion by May 9, 2024.
Source · Based on the filing body and exhibits
1st NYSE Primary Listing Transition and Listing Changes
CRH said shareholders approved the company's transition to a primary listing on the NYSE at an extraordinary general meeting on June 8, 2023, which is the 1st listing change, and that the listing changes took effect on September 25, 2023. The company said North America accounts for about 75% of Adjusted EBITDA.
Source · Based on the filing body and exhibits
2024 Annual General Meeting Schedule and Proposals
The company said it will hold its April 25, 2024 annual general meeting to vote on 7 items, including the re-election of 13 directors and an advisory vote on executive compensation. The record date for voting rights is March 14, 2024, and the Board recommends voting in favor of all items.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…